Kwality Pharmaceuticals Ltd Stock Price Today (NSE: KPL)
Fundamental Score
Kwality Pharmaceuticals Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Kwality Pharmaceuticals Ltd share price today is ₹2293.90, up +3.36% on NSE/BSE as of 19 June 2026. Kwality Pharmaceuticals Ltd (KPL) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹958.14 (Cr). The 52-week high for KPL share price is ₹2389.70 and the 52-week low is ₹828.80. At a P/E ratio of 19.53x, KPL is currently trading below its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 16.31% and a debt-to-equity ratio of 0.38.
Kwality Pharmaceuticals Ltd Share Price Chart — NSE/BSE Historical Performance
Kwality Pharmaceuticals Ltd share price chart: 40.67% return over the past month. 52-week high ₹2389.70, 52-week low ₹828.80.
Kwality Pharmaceuticals Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹2219.30 | ₹2321.00 | ₹2180.00 | ₹2293.90 | 7.86K (Cr) | |
| ₹2389.70 | ₹2389.70 | ₹2185.00 | ₹2219.30 | 15.76K (Cr) | |
| ₹2241.20 | ₹2351.00 | ₹2176.95 | ₹2310.35 | 16.01K (Cr) | |
| ₹2161.25 | ₹2290.00 | ₹2161.25 | ₹2240.85 | 14.24K (Cr) | |
| ₹2279.95 | ₹2299.10 | ₹2131.10 | ₹2164.05 | 7.46K (Cr) | |
| ₹2146.05 | ₹2315.00 | ₹2146.05 | ₹2230.55 | 13.37K (Cr) | |
| ₹2110.00 | ₹2141.15 | ₹2062.55 | ₹2135.15 | 8.12K (Cr) | |
| ₹2105.95 | ₹2157.05 | ₹2039.80 | ₹2087.40 | 6.98K (Cr) | |
| ₹2113.50 | ₹2206.55 | ₹2008.55 | ₹2055.85 | 48.94K (Cr) | |
| ₹1868.45 | ₹2051.20 | ₹1680.00 | ₹1998.55 | 67.06K (Cr) |
Kwality Pharmaceuticals Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹2389.70 | ₹2389.70 | ₹2180.00 | ₹2293.90 | -4.01% | |
| ₹1582.30 | ₹2351.00 | ₹1466.20 | ₹2310.35 | +46.01% | |
| ₹1350.00 | ₹1782.00 | ₹1335.55 | ₹1581.45 | +17.14% | |
| ₹1436.00 | ₹1740.00 | ₹1270.00 | ₹1306.35 | -9.03% | |
| ₹1079.95 | ₹1599.00 | ₹1032.30 | ₹1555.85 | +44.07% | |
| ₹1120.00 | ₹1188.00 | ₹1020.00 | ₹1065.30 | -4.88% | |
| ₹929.00 | ₹1200.00 | ₹851.95 | ₹1108.35 | +19.31% | |
| ₹898.00 | ₹1010.45 | ₹828.80 | ₹931.45 | +3.72% | |
| ₹910.05 | ₹935.00 | ₹840.00 | ₹893.25 | -1.85% | |
| ₹980.05 | ₹1004.80 | ₹885.10 | ₹920.10 | -6.12% | |
| ₹1141.00 | ₹1159.00 | ₹974.10 | ₹990.45 | -13.19% | |
| ₹1073.40 | ₹1235.00 | ₹1051.55 | ₹1144.90 | +6.66% |
AI Research Briefing
Powered by Gemini · 2026-04-15
Kwality is a generics exporter with a biologics dream, but the valuation leaves little room for error.
WHAT'S HAPPENING NOW (last 2-4 weeks)
No major catalysts found after live search. Kwality Pharmaceuticals closed its trading window on April 1st in anticipation of the FY26 audited results. The stock price moved down by -3.61% on April 13, 2026.
CORE STORY (THE REAL GAME)
Kwality Pharmaceuticals is being priced as a high-growth, high-margin generics exporter with a potential kicker from its entry into biologics. The market sees it as a company transitioning from a pure generics player to one with higher-value products and global reach.
- Strong Q3 FY26 results with significant profit growth
- Expansion into high-margin products, including biologics
- Bullish technical trend shifted in February 2026
- Successful launch and commercialization of Erythropoietin
- Significant order wins in international markets
- Faster-than-expected growth in the Indian pharmaceutical market
- Micro-cap liquidity risk
- Reliance on generics exposes them to pricing pressure
- Potential delays or competition in biologics launch
No significant change in FII/DII holdings.
The Indian pharmaceutical industry is poised for growth, driven by innovation and government support.
Yes. Free Cash Flow 5Y: ₹49.52 Cr.
Over the next 3-6 months, watch for progress on the biologics launch and any signs of pricing pressure in generics. Key will be FY27 guidance.
Primary Thesis Risk
Failure to successfully launch biologics will lead to a derating.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Kwality Pharmaceuticals Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Kwality Pharmaceuticals Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of KPL across key market metrics for learning purposes.
Positive Indicators
13 factors identified
Strong Return on Equity (16.31%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (18.40%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (24.78%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Attractive Valuation (P/E: 19.53 vs Industry: 31.77)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Robust Profit Growth (66.71%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (23.35%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Consistent Growth Track Record (21.59% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Excellent EPS Growth (37.04% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (37.04% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Strong Interest Coverage (7.41x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Strong Cash Generation (₹49.52 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (54.83%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
2 factors identified
Limited Institutional Interest (FII+DII: 0.33%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Kwality Pharmaceuticals Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Kwality Pharmaceuticals Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
69.7/100 | ₹2293.90₹2294 | ₹958.14₹958.14 | 19.53Average 19.5 Average | 16.31%Good 16.31% Good | 18.40%Good 18.40% Good | 0.38Excellent 0.4 Excellent | 37.04%Excellent 37.04% Excellent | 21.59%Excellent 21.59% Excellent | 0.00% | |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 65.2/100 | ₹1844.30₹1844 | ₹433738.68₹433738.68 | 37.57Average 37.6 Average | 16.86%Good 16.86% Good | 20.21%Excellent 20.21% Excellent | 0.07Excellent 0.1 Excellent | 23.78%Excellent 23.78% Excellent | 9.87%Good 9.87% Good | 0.89% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 67.9/100 | ₹6797.50₹6798 | ₹170445.88₹170445.88 | 68.59Average 68.6 Average | 15.35%Good 15.35% Good | 20.44%Excellent 20.44% Excellent | 0.01Excellent 0.0 Excellent | 10.41%Good 10.41% Good | 11.65%Good 11.65% Good | 0.47% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 65.3/100 | ₹4537.80₹4538 | ₹126430.62₹126430.62 | 58.36Average 58.4 Average | 26.52%Excellent 26.52% Excellent | 27.05%Excellent 27.05% Excellent | 0.33Excellent 0.3 Excellent | 13.84%Good 13.84% Good | 7.72%Good 7.72% Good | 0.86% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 59/100 | ₹1418.20₹1418 | ₹123059.76₹123059.76 | 22.62Average 22.6 Average | 17.77%Good 17.77% Good | 22.72%Excellent 22.72% Excellent | 0.01Excellent 0.0 Excellent | 28.68%Excellent 28.68% Excellent | 9.97%Good 9.97% Good | 0.85% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 59.2/100 | ₹1319.00₹1319 | ₹105224.96₹105224.96 | 18.23Average 18.2 Average | 17.96%Good 17.96% Good | 22.69%Excellent 22.69% Excellent | 0.16Excellent 0.2 Excellent | 22.28%Excellent 22.28% Excellent | 13.26%Good 13.26% Good | 0.63% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 66.7/100 | ₹2276.40₹2276 | ₹95148.15₹95148.15 | 22.00Average 22.0 Average | 20.62%Excellent 20.62% Excellent | 21.30%Excellent 21.30% Excellent | 0.32Excellent 0.3 Excellent | 54.88%Excellent 54.88% Excellent | 8.11%Good 8.11% Good | 0.58% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 68.7/100 | ₹956.95₹957 | ₹94253.78₹94253.78 | 18.74Average 18.7 Average | 21.21%Excellent 21.21% Excellent | 24.31%Excellent 24.31% Excellent | 0.38Excellent 0.4 Excellent | 25.92%Excellent 25.92% Excellent | 10.27%Good 10.27% Good | 1.17% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 50.6/100 | ₹2420.40₹2420 | ₹92012.53₹92012.53 | 52.62Average 52.6 Average | 14.68%Average 14.68% Average | 15.98%Good 15.98% Good | 0.55Good 0.6 Good | 11.73%Good 11.73% Good | 15.79%Excellent 15.79% Excellent | 0.04% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 28.8/100 | ₹1435.90₹1436 | ₹70798.69₹70798.69 | 20.69Average 20.7 Average | 11.08%Average 11.08% Average | 14.18%Average 14.18% Average | 0.22Excellent 0.2 Excellent | 3.87%Average 3.87% Average | 6.55%Good 6.55% Good | 0.33% |
Alkem Laboratories LtdAlkem Laborator... ALKEM • 539523 | 59.5/100 | ₹5451.50₹5452 | ₹67075.29₹67075.29 | 28.54Average 28.5 Average | 19.39%Good 19.39% Good | 20.38%Excellent 20.38% Excellent | 0.18Excellent 0.2 Excellent | 13.93%Good 13.93% Good | 9.21%Good 9.21% Good | 0.80% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price433738.68 Cr
- Divis Laboratories Ltd share price170445.88 Cr
- Torrent Pharmaceuticals Ltd share price126430.62 Cr
- Cipla Ltd share price123059.76 Cr
- Dr Reddys Laboratories Ltd share price105224.96 Cr
Kwality Pharmaceuticals Ltd PE Ratio History
Historical price-to-earnings ratio for KPL — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹38.36 | ₹1108.35 | 28.9x |
| FY 2024 | ₹22.76 | ₹866.80 | 38.1x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Kwality Pharmaceuticals Ltd Quarterly Performance
Latest quarterly metrics for KPL — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
23.35%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
66.71%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
21.59%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
37.04%
Compounded annual net profit growth over 5 years
Kwality Pharmaceuticals Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for KPL — calculated from daily price history
Momentum is strong — price may be stretched. Watch for pullbacks.
Technical indicators are for educational purposes only. Not investment advice.
Kwality Pharmaceuticals Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Kwality Pharmaceuticals Ltd (KPL) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Kwality Pharmaceuticals Ltd
About KPL (Kwality Pharmaceuticals Ltd)
Kwality Pharmaceuticals Ltd is a dynamic and multifaceted pharmaceutical enterprise dedicated to crafting and distributing a wide spectrum of high-quality medicinal formulations. W...ith a commitment to innovation and patient well-being, the company meticulously develops and manufactures its products to meet stringent global standards. From advanced research and development initiatives to sophisticated manufacturing processes, Kwality Pharmaceuticals strives to deliver reliable and effective healthcare solutions across diverse therapeutic areas. The company operates with a core focus on integrity, transparency, and ethical practices, ensuring that its products contribute positively to the health and wellness of communities worldwide. Kwality Pharmaceuticals is poised to address evolving healthcare needs with a portfolio of pharmaceutical offerings. Kwality Pharmaceuticals' robust manufacturing capabilities are reflected in its diverse range of dosage forms. The company excels in producing liquid orals, catering to patients who prefer easy administration. Dry syrups and powders for oral suspension offer flexible dosing options, while tablets and capsules remain staples for convenient consumption. For specialized needs, Kwality Pharmaceuticals manufactures sterile powders for injection, along with small volume parentals in both liquid and lyophilized forms. The company further demonstrates its versatility with pre-filled syringes, ointments, creams, and ophthalmic preparations such as eye and ear drops. Kwality Pharmaceuticals also produces sanitizers, suppositories, injectable vials and ampoules. Underpinning Kwality Pharmaceuticals' operations is a steadfast dedication to quality control and regulatory compliance. The company adheres to stringent Good Manufacturing Practices (GMP) across all its facilities, ensuring that every product meets the highest benchmarks for safety, efficacy, and purity. Through continuous monitoring, rigorous testing, and ongoing improvement initiatives, Kwality Pharmaceuticals maintains the integrity of its manufacturing processes and reinforces its commitment to delivering trustworthy pharmaceutical solutions. By prioritizing quality at every stage, Kwality Pharmaceuticals strives to earn the confidence of healthcare professionals and patients alike, solidifying its position as a reliable partner in healthcare.
Company Details
Key Leadership
Corporate Events
Latest News
KPL Share Price: Frequently Asked Questions
What is the current share price of Kwality Pharmaceuticals Ltd?
Kwality Pharmaceuticals Ltd (KPL) trades at ₹2293.90 on NSE and BSE. Market cap ₹958.14 (Cr). Educational data only.
What is the P/E ratio of Kwality Pharmaceuticals Ltd?
Kwality Pharmaceuticals Ltd has a P/E of 19.53x vs industry average 31.77x.
What is the Bull Run score for Kwality Pharmaceuticals Ltd?
Kwality Pharmaceuticals Ltd has a Bull Run score of 69.7/100 based on 25+ financial parameters.
Does Kwality Pharmaceuticals Ltd pay dividends?
Kwality Pharmaceuticals Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Kwality Pharmaceuticals Ltd?
Kwality Pharmaceuticals Ltd has ROE of 16.31%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Kwality Pharmaceuticals Ltd?
Kwality Pharmaceuticals Ltd has debt-to-equity of 0.38.
Is Kwality Pharmaceuticals Ltd a good investment?
Bull Run gives Kwality Pharmaceuticals Ltd a score of 69.7/100. This is not investment advice — consult a SEBI-registered advisor.